Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-12-19
2008-12-23
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S262200
Reexamination Certificate
active
07468385
ABSTRACT:
The present invention relates to triazole derivatives of formula (I) notably for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such triazole derivatives. Said triazoles are useful in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. In particular, the present invention is related to triazole derivatives displaying a substantial modulatory, in particular antagonistic activity, of the oxytocin and/or vasopressin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin and/or vasopressin. The present invention is furthermore related to novel triazole derivatives as well as to methods of their preparation.
REFERENCES:
patent: 5336778 (1994-08-01), Ashton et al.
patent: 5756497 (1998-05-01), Bell et al.
patent: 6346532 (2002-02-01), Maruyama et al.
patent: 2005/0187275 (2005-08-01), Quattropani et al.
patent: 048 555 (1982-03-01), None
patent: 409 332 (1991-01-01), None
patent: 469 984 (1992-02-01), None
patent: 505 111 (1992-09-01), None
patent: 526 348 (1993-02-01), None
patent: 96/22775 (1996-08-01), None
patent: 00/46220 (2000-08-01), None
patent: 01/58880 (2001-08-01), None
Doug W. Hobbs, et al., “Non-peptide oxytocin antagonists: identification and synthesis of a potent camphor aminosuccinimide”, Bioorganic & Medicinal Chemistry Letters, vol. 5, No. 2, pp. 119-122 Jan. 19, 1995.
M. Thibonnier, et al., Annu. Rev. Pharmacol. Toxicol., vol. 41, pp. 175-202 2001.
Mariel Birnbaumer, TEM, vol. 11, No. 10, pp. 406-410 2000.
Mario Maggi, et al., Journal of Clinical Endocrinology and Metabolism, vol. 70, No. 4, pp. 1142-1154 1990.
B. F. Mitchell, et al., Society for Gynecologic Investigation, vol. 8, No. 3, pp. 122-133 2001.
Marc Thibonnier, et al., Adv. Exp. Med. Biolog., vol. 449, pp. 251-276 1998.
Steven Thornton, et al., Experimental Physiology, vol. 86, No. 2, pp. 297-302 2001.
Ben E. Evans, et al., J. Med. Chem., vol. 35, pp. 3919-3927 1992.
O.S. Moustafa, Heterocycl. Commun., vol. 6, No. 5, pp. 465-471 2000.
Wallace T. Ashton, et al., Journal of Medicinal Chemistry, vol. 36, No. 5, pp. 591-609 1993.
Paul C. Fritch, et al., Solid-Phase Org. Synth., vol. 1, pp. 105-112 2001.
Dr. Neil Cook, et al., Pharmaceutical Manufacturing International, pp. 49-53 1992.
Gerald Gimpl, et al., Physiological Reviews, vol. 81, No. 2, pp. 629-683 2001.
U.S. Appl. No. 11/449,802, filed Jun. 9, 2006, Schwarz et al.
Coulter Thomas
Quattropani Anna
Schwarz Matthias
Thomas Russell J.
Chung Susannah
Laboratoires Serono SA
McKane Joseph K.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Triazoles as oxytocin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triazoles as oxytocin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazoles as oxytocin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4022647